AMENDMENT NO. 3 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to LICENSING AND ASSIGNMENT AGREEMENT, made and entered into the 6th day of October, 2017 (“Amendment No. 3 Effective Date”) by and between Satsuma Pharmaceuticals, Inc., having its principal place of business at 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA (“Company”) and Shin Nippon Biomedical Laboratories, Ltd., having its principal place of business at 2438, Miyanoura-cho, Kagoshima-shi, Kagoshima-ken, Japan (“SNBL”). Company and SNBL are collectively the “Parties”.
AMENDMENT NO. l TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 16th, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. l (“Amendment No. l”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of January 13, 2017 (“Amendment No. l Effective Date”)
AMENDMENT NO. 2 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 2nd, 2019 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of April 27, 2017 (“Amendment No. 2 Effective Date”)
AMENDMENT NO.4 TO LICENSING AND ASSIGNMENT AGREEMENTLicensing and Assignment Agreement • August 11th, 2020 • Satsuma Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No.4 (“Amendment No.4”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of May 25, 2020 (“Amendment No.4 Effective Date”).
